New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36637483.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3640 and PMC identifier 10023384.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibody-drug conjugates (ADC) allow the delivery of cytotoxic chemotherapeutic agents to tumors. Two ADC delivering topoisomerase I (TOP1) poisons (Enhertu and Trodelvy) have recently been FDA-approved for Her2- and Trop2-expressing solid tumors. In a recent study, a TOP1-anti B7-H4 ADC was described and shown to be synergistic with a novel PARP1-selective inhibitor. See related article by Kinneer et al., p. 1086.
Medical subject headings
- Immunoconjugates
- Neoplasms